Abstract
Sarcomas are a diverse set of malignancies. For soft tissue sarcomas, the kinase and chaperone inhibitor pazopanib is a standard of care therapeutic. Previously, we demonstrated that HDAC inhibitors enhanced pazopanib lethality against sarcoma and other tumor cell types in vitro and in vivo. The present studies defined mechanisms of drug-combination resistance. Exposure of sarcoma and PDX ovarian carcinoma cells to [pazopanib + entinostat] caused a prolonged activation of ERBB1 and transient/prolonged activations of ERBB2, c-KIT, and c-MET, in a cell-specific fashion. The activities of mTORC1, mTORC2, GRP78, HSP90, and HSP70 were reduced, expression of Beclin1 and ATG5 enhanced, and the ATM-AMPK-ULK1-ATG13-Beclin1/ATG5 pathway activated. Inhibition of ERBB1/2/4 using neratinib or of c-MET using crizotinib significantly enhanced [pazopanib + entinostat] lethality. For neratinib with [pazopanib + entinostat], this effect correlated with reduced phosphorylation and expression of ERBB1, ERBB2, c-KIT, and c-MET and reduced expression, regardless of mutational status, of N-RAS and K-RAS. [Pazopanib + entinostat + neratinib] reduced the phosphorylation of the Hippo pathway proteins MST1/3/4 and MOB1 whereas this treatment increased th...Continue Reading
References
Apr 23, 2009·Cellular Signalling·Thomas Grewal, Carlos Enrich
Nov 1, 2011·Nature Biotechnology·Mindy I DavisPatrick P Zarrinkar
May 19, 2012·Lancet·Winette T A van der GraafUNKNOWN PALETTE study group
Feb 22, 2014·Cancer Biology & Therapy·Seyedmehrad TavallaiPaul Dent
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jun 9, 2015·Biochimica Et Biophysica Acta·Abdalla D MohamedHenning Wackerhage
Jun 13, 2015·Applied Immunohistochemistry & Molecular Morphology : AIMM·Asmaa G AbdouAmal F Abd Eldayem
Sep 16, 2015·The Journal of Cell Biology·Barry J Thompson, Erik Sahai
Sep 22, 2015·Frontiers in Oncology·Michael D DeelCorinne M Linardic
Oct 6, 2015·Nature Communications·Zhipeng MengKun-Liang Guan
Oct 28, 2015·Oncotarget·Ju-Fang LiuChun-Han Hou
Feb 18, 2016·Oncotarget·Laurence BoothPaul Dent
Mar 31, 2016·PloS One·Oliver H WangAnirban Maitra
Apr 30, 2016·Oncotarget·Colleen A FullenkampMunir R Tanas
Feb 2, 2017·Oncotarget·Laurence BoothPaul Dent
Sep 9, 2017·Oncotarget·Ying TangDai-Han Zhou
Nov 16, 2017·Oncotarget·Laurence BoothPaul Dent
Nov 23, 2017·Oncotarget·Laurence BoothPaul Dent
Feb 3, 2018·Cancer Biology & Therapy·Alexcia Camila BraunLudmilla Thomé Domingos Chinen
Mar 7, 2018·Nature Communications·Cynthia L HsuAlbert R La Spada
Jun 14, 2018·Aging and Disease·Sheng ChenJianmin Zhang
Aug 2, 2018·Oncology Reports·Jialin ZhuPeng Xu
Sep 12, 2018·Journal of Cellular Physiology·Laurence BoothPaul Dent
Oct 5, 2018·Current Opinion in Immunology·Jennifer Martinez
Nov 2, 2018·Cell Death & Disease·Adrian Rivera-ReyesT S Karin Eisinger-Mathason
Dec 21, 2018·Cancer Biology & Therapy·Laurence BoothPaul Dent
Feb 3, 2019·Cancer Discovery·Ophélia MaertensKaren Cichowski
Jun 9, 2019·Trends in Cancer·Chan D K Nguyen, Chunling Yi
Citations
Oct 22, 2020·Cell Death & Disease·Dongying WangTianmin Xu
Sep 15, 2019·Cellular Signalling·Paul DentJohn F Hancock
Jun 7, 2020·Biochemical Pharmacology·Laurence BoothPaul Dent
Jul 1, 2021·Signal Transduction and Targeted Therapy·Victoria DamerellSharon Prince
Jan 9, 2020·Cellular Signalling·Paul DentJohn F Hancock
Oct 5, 2021·Frontiers in Oncology·Jane L RobertsPaul Dent